Mechanism

TrialResults-center.org

Menu

vasopeptidase inhibitor

Omapatrilat

heart failure, in all type of patients

Endpoint	TE [95% CI]	p val	I2	n	k
Death from any cause or hospitalization for heart failure	no data
cardiovascular events	no data
hospitalisation for heart failure	no data
All cause death	no data

Trial	Studied treatment	Control	Patients
OVERTURE, 2002	omapatrilat 40 mg once dailyitm	enalapril 10 mg twice daily	patients with NYHA II-IV heart failure

Omapatrilat

Death from any cause or hospitalization for heart failure by 48% suggested

Endpoint	TE [95% CI]	p val	I2	n	k
Death from any cause or hospitalization for heart failure	0.52 [0.27 1.00]	p=0.04	0	573	1	IMPRESS,
cardiovascular events	no data
hospitalisation for heart failure	0.44 [0.19 1.02]	p=1.00	0	573	1	IMPRESS,
All cause death	0.69 [0.26 1.83]	p=1.00	0	573	1	IMPRESS,

Trial	Studied treatment	Control	Patients
IMPRESS, 2000	omapatrilat target dose 40 mg daily	lisinopril target dose 20mg daily	patients with NTHA II-IV congestive heart failure, LEVF <=40%, and receiving ACE inhibitor

Modal title

- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy -